Korean Journal of Gastrointestinal Endoscopy 2000;21(5): 832-837.
Helicobacter pylori 제균치료에 Rebamipide ( Mucosta ) 의 유용성 ( Effect of Rebamipide ( Mucosta ) in Eradication of Helicobacter pylori )
이강문(Kang Moon Lee),이동수(Dong Soo Lee),정일권(Il Gwon Jung),이문호(Moon Ho Lee),안병민(Byung Min An),정현용(Hyun Yong Jung),노임환(Im Hwan Rho),남승우(Seung Woo Nam),이재동(Jae Dong Lee)
Abstract
Bakground/Aims: Eradication of Helicobacter pylori infection is highly efficacious in preventing the recurrence of peptic ulcer. Rebamipide (Mucosta) is known to have the ability to inhibit neutrophil activity, to reduce the production of inflammatory cytokines, to scavenge oxygen radical, and to stimulate prostaglandin production. This study was designed to evaluate the effect of rebamipide on the eradication of H. pylori, and decrease of the infilatration of inflammatory cells. Methods: Eighty two patients with gastric or duodenal ulcers with H. pylori infection were allocated to two treatment groups. The patients were treated either with omeprazole 40 mg, clarithromycin 1.0 g, amoxicillin 2.0 g, rebamipide 300 mg (OCAR group) or omeprazole 40 mg, clarithromycin 1.0 g, amoxicillin 2.0 g (OCA group) for two weeks. Results: H. pylori was eradicated 56 out of 62 patients (90%) in OCAR group and 16 out of 20 patients (80%) in OCA group. The infiltration of inflammatory cells decreased in both treatment groups. No significant side effects had been noticed. Conclusions: The results of the present study suggest that rebamipide may be useful to decrease gastric mucosal inflammation in peptic ulcer disease. However, further detailed study will be reqiured to determine the potentially beneficial effect whether rebamipide can prevent the recurrence of peptic ulcer diseases with H. pylori infection.
PDF Links
Full text via DOI 
Download Citation 
